RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.33%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$740M
AUM Growth
+$740M
(-5.5%)
Cap. Flow
-$98.9M
Cap. Flow
% of AUM
-13.36%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$10.2M |
| 2 |
Gilead Sciences
GILD
|
$9.33M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$9.05M |
| 4 |
Cencora
COR
|
$8.66M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$6.55M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$30.6M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.4M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$10.1M |
| 4 |
AET
Aetna Inc
AET
|
$9.86M |
| 5 |
CVS Health
CVS
|
$9.76M |
Sector Composition
| 1 | Healthcare | 90.07% |
| 2 | Financials | 0.19% |
| 3 | Technology | 0.17% |
| 4 | Energy | 0.14% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
26
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $10.3M | 1.39% |
211,153
-86,247
| -29% | -$4.2M |
|
|
27
Acadia Pharmaceuticals
ACAD
$4.34B
| $10.2M | 1.38% |
+338,882
| New | +$10.2M |
|
|
AGN
28
DELISTED
Allergan plc
AGN
| $9.66M | 1.31% |
59,052
-40,948
| -41% | -$6.7M |
|
29
NovoCure
NVCR
$1.35B
| $9.45M | 1.28% |
467,569
-198,959
| -30% | -$4.02M |
|
30
Cigna
CI
$80.2B
| $9.22M | 1.25% |
45,400
-9,600
| -17% | -$1.95M |
|
31
Neurocrine Biosciences
NBIX
$13.5B
| $9.15M | 1.24% |
117,969
+2,969
| +3% | +$230K |
|
32
Boston Scientific
BSX
$159B
| $8.63M | 1.17% |
347,968
+67,500
| +24% | +$1.67M |
|
33
Edwards Lifesciences
EW
$47.7B
| $8.27M | 1.12% |
73,364
-6,636
| -8% | -$748K |
|
34
FibroGen
FGEN
$48.4M
| $8.04M | 1.09% |
169,547
+24,047
| +17% | +$1.14M |
|
35
Bristol-Myers Squibb
BMY
$96.7B
| $7.95M | 1.07% |
129,802
-30,700
| -19% | -$1.88M |
|
|
IMMU
36
DELISTED
Immunomedics Inc
IMMU
| $7.76M | 1.05% |
480,330
-19,670
| -4% | -$318K |
|
|
LOXO
37
DELISTED
Loxo Oncology, Inc
LOXO
| $7.6M | 1.03% |
90,280
+15,280
| +20% | +$1.29M |
|
|
AERI
38
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $7.58M | 1.02% |
126,829
+5,897
| +5% | +$352K |
|
39
Iovance Biotherapeutics
IOVA
$800M
| $7.55M | 1.02% |
944,185
+233,022
| +33% | +$1.86M |
|
|
MYOK
40
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $7.51M | 1.01% |
178,272
+27,400
| +18% | +$1.15M |
|
41
Rigel Pharmaceuticals
RIGL
$710M
| $7.5M | 1.01% |
1,932,831
-417,169
| -18% | -$1.62M |
|
42
Alnylam Pharmaceuticals
ALNY
$58.6B
| $7.49M | 1.01% |
58,967
+16,174
| +38% | +$2.05M |
|
43
Elevance Health
ELV
$72.4B
| $6.98M | 0.94% |
31,000
-24,000
| -44% | -$5.4M |
|
44
Abbott
ABT
$230B
| $6.96M | 0.94% |
122,000
-33,000
| -21% | -$1.88M |
|
45
Xencor
XNCR
$594M
| $6.96M | 0.94% |
317,500
+67,500
| +27% | +$1.48M |
|
|
FLXN
46
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $6.55M | 0.89% |
+261,686
| New | +$6.55M |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.53M | 0.88% |
182,580
-63,820
| -26% | -$2.28M |
|
|
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
| $6.44M | 0.87% |
503,059
-146,941
| -23% | -$1.88M |
|
49
Universal Health Services
UHS
$11.6B
| $5.94M | 0.8% |
52,433
+2,433
| +5% | +$276K |
|
50
MacroGenics
MGNX
$121M
| $5.86M | 0.79% |
308,604
+86,690
| +39% | +$1.65M |
|